SLDB - Solid Biosciences Inc.
IEX Last Trade
4.33
0.035 0.808%
Share volume: 42,378
Last Updated: Thu 26 Dec 2024 08:29:50 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$4.30
0.04
0.81%
Fundamental analysis
10%
Profitability
0%
Dept financing
6%
Liquidity
50%
Performance
10%
Performance
5 Days
1.95%
1 Month
-27.68%
3 Months
-42.50%
6 Months
-26.67%
1 Year
-32.36%
2 Year
-20.68%
Key data
Stock price
$4.33
DAY RANGE
$4.06 - $4.33
52 WEEK RANGE
$4.16 - $15.05
52 WEEK CHANGE
-$37.89
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Ilan Ganot
Region: US
Website: solidbio.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: solidbio.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles.
Recent news